AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research's Tumor Immunology and Immunotherapy Conference

AgilVax Inc., a biopharmaceutical company that discovers and develops targeted antibody-based therapeutics, announced today that preclinical data describing M5, the Company's monoclonal antibody targeting xCT, will be presented by Dr. Salameh at the American Association for Cancer Research's Tumor Immunology and Immunotherapy Conference being held at the Boston Marriott Copley Place in Boston, MA.

"We are pleased with our continued progress on developing multiple solutions to target cancer cells overexpressing xCT and thrilled to have the opportunity to showcase our advancements in a poster presentation at such a prestigious meeting," said Dr. Joseph Patti, President and CEO of AgilVax. Dr. Patti further stated, "xCT overexpression occurs in several cancers leading to metabolic changes that reprograms cells for growth and progression. AgilVax's antibody-based therapeutics have shown reduction of primary tumor formation and lung metastases illustrating the potential to create durable responses in patients suffering from colorectal and other metastatic cancers."

About AgilVax

AgilVax is a biopharmaceutical company that discover and develops targeted antibody-based products to treat multiple types of cancer. The Company has three development programs; an unmodified monoclonal antibody (mAb) targeting xCT, an antibody-drug conjugate targeting xCT, and AX09, a VLP-based xCT vaccine currently in cGMP production.

For more information, please visit http://www.agilvax.com